The Fujifilm Group is set to make major progress as a comprehensive healthcare company 2 years after its full entry into the pharmaceutical business.
Note: The article on this page is taken from Sustainability Report 2011.
Creating New Value through Greater Cooperation
within the Group
The Fujifilm Group is set to make major progress as a comprehensive healthcare company 2 years after its full entry into the pharmaceutical business. Aiming at the development of original advanced technologies, we are encouraging increased cooperation among Group companies including FUJIFILM Corporation, Toyama Chemical, FUJIFILM RI Pharma, and FUJIFILM Pharma.
2010: The year we moved forward as a comprehensive healthcare company
The Fujifilm Group fully entered the pharmaceutical business in 2008, welcoming Toyama Chemical to the Group. The year 2010 was one filled with dynamic changes focused on accelerating our activities as a comprehensive healthcare company. In June 2010, the Pharmaceutical Products Division was established to unify all of our pharmaceutical business. Also, the Drug Discovery Research Laboratories and the Life Science Research Laboratories were unified into the Pharmaceutical and Healthcare Research Laboratories. Further progress was made in creating a system for wide-ranging pharmaceutical business with, for example, the inception of FUJIFILM Pharma, which develops and sells high-value-added generic pharmaceutical products, and a capital alliance with Japan Tissue Engineering, a pioneer in regenerative medicine.
Fujifilm's Pharmaceutical Products Division: Its role and systems
Toward a unique pharmaceutical business
The Pharmaceutical Products Division was established in June 2010 to make significant headway as a comprehensive healthcare company. The division has two roles, expanding Fujifilm's pharmaceutical business and unifying management of the Group companies involved in its pharmaceutical business.
To expand the business, the division not only creates basic strategies for the Fujifilm Group's pharmaceutical business, such as promoting overseas business, creating and executing M&As and licensing strategies, and improving mechanisms for cross-group research and development, it also specifies the Group's business domain and constructs new business models.
For unified management of Group companies in our pharmaceutical business, the division manages business planning, research, production, pharmaceutical affairs, and systems assuring product quality. The division is building a unified management system for the Group as part of its functions for company headquarters. Based on such concepts as optimization for the entire Group and creating a sense of unity in the Group, the division has set up an R&D Committee, a Production System Committee, a Licensing Committee, a Pharmaceutical Affairs Committee, and a liaison conference for Group companies in the pharmaceutical business.
The division will pursue unique pharmaceutical business by taking advantage of the technological resources of Fujifilm and the strengths of Group companies and by organizing the Group's best efforts.
Fujifilm's Pharmaceutical Products Division and Group companies
Research and development at the Fujifilm Group
Goals for the Pharmaceutical Products Division
Similarities between photographic film technology and healthcare
Director Senior Vice President
The successful launching of a new business hinges on three key terms: “can do”, “should do”, and “want to do”. The reason why we made a significant change in our course is because these three keywords clearly applied to our business.
The key term “can do” represents a company's potential. Fujifilm has been involved with healthcare through its production of X-ray film since 1936, soon after the company's inception. We have strong ties with medical practice, and we continue to maintain the largest share in the domestic market as a provider of medical imaging information systems.
Photographic technology is similar to pharmaceutical technology in its use of fine chemicals.* We have assembled a one-of-a-kind chemical library of 200,000 compounds through our photographic film business. The library contains a number of compounds that can potentially be used in pharmaceutical products, such as pigments with antineoplastic properties. Also, collagen, which is a main component of skin, cartilage, and ligament, is a substrate of film, and technologies for manufacturing collagen are expected to be applied in regenerative medicine. Our original nanotechnologies that make high-level emulsification and dispersion possible can be applied to FTD (formulation, targeting, and delivery) technology, which can deliver chemical compounds to targeted areas in appropriate form, quantity, and timing. As many as 100 kinds of chemical compounds are used for film approximately 18 microns thick, and it cannot function as a product without their complex interactions. The enormous number of technologies accumulated for photographic film is indeed a mountain of treasure. It is our duty to utilize these technologies in closely related medical fields and not to consider them merely as legacies of the past.
The key term “should do” represents marketability. With populations aging worldwide, increased healthcare costs have become a serious social issue, and people's medical needs and views on health are shifting significantly. The future requires us to consider healthcare in a comprehensive framework consisting of prevention, diagnosis, and treatment, and the Fujifilm Group has technologies that can contribute to each of these aspects. As the number of new drugs developed declines year on year, we believe that companies like us with technological potential from a different industry are now in demand. This belief has been borne out by the external encouragement we have received regarding our entry into the healthcare industry.
The key term “want to do” reflects passion and a sense of responsibility. The Pharmaceutical Products Division is relishing the task of changing healthcare with our original technologies.
* Fine chemicals : Pure substances with added value which have been processed for specialized applications.
Relationships between “can do”, “should do”, and “want to do”
The Fujifilm Group's solution to influenza treatment
Creating unique pharmaceutical products through interactions between first-rate personnel
With the ambitious plan of becoming a comprehensive healthcare company, we need to focus on our specialized fields and increase the efficiency and speed of our business. To realize this, the Pharmaceutical Products Division has conducted many projects involving different companies and departments, and has produced some extremely positive results.
One such example is the development of an advanced influenza treatment system. The system combines the new drug T-705 developed by Toyama Chemical for suppressing viral growth and a high-sensitivity diagnostic agent to which Fujifilm's photographic amplification technology is applied. Also, the Pharmaceutical and Healthcare Research Laboratories and other research centers have been actively conducting research and development of not only advanced technologies for treating cancer, central nervous system diseases, and inflammatory diseases, but also generic drugs with increased functionality utilizing our FTD technology.
At the same time, we are actively establishing and maintaining overseas sites so that we can conduct clinical tests in foreign countries, which have different pharmaceutical laws, and expand our business widely in overseas markets in the future. The strong operation of the newly established Pharmaceutical Products Division can be attributed to employees actively interacting with each other across the Group's companies. For instance, Toyama Chemical has a group of excellent researchers highly capable of identifying and judging the potential usefulness of materials for new drugs and finding the shortest path to product release, and has created numerous original new drugs. FUJIFILM Pharma is specialized in development and sales, with professionals who have detailed knowledge of the pharmaceutical industry and are more than ready to take on a challenge. Every employee is a first-rate professional with a diverse range of skills, and synergy arises from friendly competition. We are confident that we have established a strong team for unique new drug development.
We will approach research and development of pharmaceutical products from a creative perspective unrivaled by other pharmaceutical companies because we came from a different industry. We will focus on contributing to improving people's quality of life in all that we do.
Creating value needed in the era of medical care
Mr. Shinsuke Muto
President, You Home Clinic,
Tetsuyu Institute Medical Corporation
Chairman, Leading Aging Society Forum
The Fujifilm Group has made its full-fledged debut into the pharmaceutical industry, and we believe that new types of needs for pharmaceutical products will arise in the future due to structural changes to society. The Fujifilm Group brings with it three strengths based on its photographic film technologies particularly applicable to these societal needs: first, its chemical library, second, its expertise in collagen-related research, which can contribute to overall enhancing quality of life, and third, its FTD technologies, which may be used to develop effective medications or improve existing ones. We hope they will align their efforts along these strengths to blaze trails through new markets, both in Japan and overseas. Likewise, I look forward to their contributions toward the solution of societal ills through innovations in integrating imaging technologies and drug development that allow us to actually see medicinal effects.
Activities at FUJIFILM Pharma
Toward new value creation
General Manager, Strategic Product Planning and Management Department, FUJIFILM Pharma Co., Ltd.
(at the time of the interview)
Operations Manager, Pharmaceutical Products Division, FUJIFILM Corporation
(from July 1, 2011)
FUJIFILM Pharma started in April 2010 with the primary responsibilities of development and sales in Fujifilm's pharmaceutical business. We started with the release of more than 170 generic pharmaceutical products and, in November, released five generic pharmaceutical products under our own brand. We now have more than 10,000 customers and recognize that the Fujifilm brand is greatly trusted in the market. Fujifilm has rigorously controlled product quality by applying its own standards, being careful not to miss a once-in-a-lifetime moment for a “great memory”. This corporate culture of achieving high product quality under self-imposed rules has influenced our pharmaceutical business too, and FUJIFILM Pharma strives to control product quality, placing emphasis on the 3 qualities of the raw materials used, the manufacturing process, and post-marketing information gathering and distribution. We chose to focus on generic pharmaceutical products because we intend to develop pharmaceutical products with high added value, using the FTD technology from among Fujifilm's advanced technologies that can be applied to pharmaceutical products. In cooperation with FUJIFILM Pharmaceutical and Healthcare Research Laboratories, we are currently developing new pharmaceutical products with better quality and efficacy than existing products. It has become difficult in recent years to launch new breakthrough drugs in the market, and the pharmaceutical industry has increasingly become a “closed” industry. Against this backdrop, various professionals who expect new things have gathered at FUJIFILM Pharma. We believe that new value is created when there is a concentration of knowledge among employees with diverse backgrounds, who work in an open corporate culture that is not constrained by existing common knowledge. FUJIFILM Pharma aims to become a comprehensive healthcare company that produces new drugs as well as generics.
Note: The article on this page is taken from Sustainability Report 2011.